Abstract
e17655 Background: There are currently few treatment options for relapsed / refractory (RR) indolent non-Hodgkin’s lymphoma (iNHL) patients. Idelalisib (IDELA) is a first-in class PI3Kδ inhibitor with substantial clinical efficacy in iNHL patients refractory to rituximab and an alkylating agent. A single-arm clinical trial (Study 101-09) showed IDELA treatment results in a median of 11 and 20.3 months of progression-free and overall survival (PFS and OS), respectively, in these RR iNHL patients. Methods: A decision-analytic model simulated a cohort of RR iNHL patients over a 1 to 5 year time horizon. Patients first received IDELA or an aggregate comparator of current RR iNHL chemotherapy regimens in a progression-free state before transitioning to a progressive-disease state where they received palliative care until death. Survival data was fit and extrapolated from Study 101-09 (IDELA). A database claims analysis provided survival, disease- and treatment-related adverse events (AEs) profiles, and medical...
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call